[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Metis Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":128},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,67,89,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100586902","assessment-of-burn-severity-and-extent-spatial-frequency-domain-imaging-100586902",false,"NCT06921421","Assessment Of Burn Severity and Extent Spatial Frequency Domain Imaging","Assessment Of Burn Severity and Extent Spatial Frequency Domain Imaging (SFDI): An Observational Pilot Study","Inclusion Criteria:\n\n1. Patients 18 years of age or older\n2. Thermal burns of any depth (superficial, deep partial thickness, or full thickness).\n\nExclusion Criteria:\n\n1. Patients less than 18 years of age\n2. Pregnant or breastfeeding women","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","OBSERVATIONAL","The goal of this pilot clinical study is to evaluate the feasibility of collecting Spatial Frequency Domain Imaging (SFDI) data in patients with circulatory compromise due to thermal burns using the FDA-cleared Clarifi Imaging System and the next generation handheld m-Clarifi. Accurate assessment of burn depth and assessment at the point of care is an essential input for clinicians to plan proper treatment and management. SFDI has been shown to be a promising method to evaluate burn depth and extent within 24 hours in pre-clinical studies. The two feasibility goals of this study are as follows: 1) Do the values obtained with a commercial SFDI system provide utility in assessing burn depth in a clinical setting? And 2) Do Clarifi and m-Clarifi provide equivalent data when assessing subjects with burn injuries (biomarker imaging values, clinical workflow).",[24,25],"Burn","Burn Injury",[27,28,29,30],"SFDI","Spatial Frequency Domain Imaging","Burn depth","Burn injury assessment","NOT_YET_RECRUITING","2025-04-08",{"date":34,"type":35},"2025-04-10","ACTUAL",{"date":37,"type":20},"2025-04",{"date":39,"type":20},"2025-12",{"name":41,"class":42},"The Metis Foundation","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100474819","suprathel-use-during-prolonged-field-care-to-promote-healing-and-reduce-the-need-for-grafting-of-burn-wounds-100474819","NCT05462860","Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds","Inclusion Criteria:\n\n* Male or Female ≥18 years and ≤75 years\n* Acute partial thickness burns by friction, contact, scalding from hot liquids and flame\n* TBSA total ≥2 %; burn treatment region of interest: all areas with partial-thickness burns excluding face, neck, scalp, and feet\n* TBSA 3rd ≤5 % (not to be included as burn treatment region of interest)\n* Subject is able and willing to sign Informed Consent or via legally authorized representative\n\nExclusion Criteria:\n\n* Study Wound due to electrical, radioactive, or frostbite-related injury\n* Infection of wounds in the study area at admission per Investigator or treating physician discretion\n* Pregnancy\u002Flactation\n* Subjects who are unable to follow the protocol or who are likely to be non-compliant\n* Participation in an active treatment arm of a burn wound related interventional study within 90 days of Screening Visit or during the study\n* Prisoners\n* Life expectancy less than 6 months\n* Subjects who are receiving steroids, chronic anticoagulants, or immune suppressive treatment","75 Years",{"count":52,"type":20},21,"INTERVENTIONAL",[55],"NA","The purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of reduction of pain, infection, provider workload, scar development and costs compared to SoC.",[58,59],"Wound of Skin","Burns","RECRUITING",{"date":34,"type":35},{"date":63,"type":35},"2024-09-18",{"date":65,"type":20},"2026-06-29",{"name":41,"class":42},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":53,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100554770","a-prospective-study-using-suprasdrm-in-promoting-healing-and-reducing-the-time-to-grafting-of-full-thickness-wounds-100554770","NCT06503406","A Prospective Study Using SupraSDRM® in Promoting Healing and Reducing the Time to Grafting of Full-thickness Wounds","Inclusion Criteria:\n\n* Patient age ≥18 years and ≤85 years\n* Full-thickness traumatic injury, surgical wound, or excised full-thickness burn (e.g., friction, contact, flame, scalding etiology), where immediate grafting is not deemed suitable by the treating surgeon\n* Wound size ≥ 5cm2 not immediately suitable for graft application\n* Subject or legally authorized representative is able and willing to sign informed consent\n\nExclusion Criteria:\n\n* Study wound may not include areas of the face, and neck and genitalia.\n* Wound with metal hardware exposure\n* Pressure sores\n* Wounds with residual malignancy\n* Wound infection at the time of planned wound dressing application\n* Wound that is a part of an active treatment arm of an interventional study (within 90 days of Screening Visit)\n* Pregnancy\u002Flactation\n* Subjects who are unable to follow the protocol or who are likely to be non-compliant\n* Subjects with uncontrolled diabetes (defined by Hgb A1C \\>10)\n* Subjects who are receiving systemic steroids or immune suppressive treatment\n* Subject with a known allergy to polylactide, polycaprolactone, polyvinyl alcohol, trimethylene carbonate or resorbable suture materials.\n* Prisoners","85 Years",{"count":75,"type":20},24,[55],"This is a prospective, randomized, controlled, multi-center clinical study comparing SupraSDRM® to standard of care wound dressing, BTM, in the treatment of full-thickness wounds deemed not immediately suitable for definitive grafting will be performed.",[79,59,80],"Surgical Wound","Trauma Injury","2025-02-19",{"date":83,"type":35},"2025-02-21",{"date":85,"type":20},"2025-03",{"date":87,"type":20},"2026-10",{"name":41,"class":42},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":96,"targetDuration":4,"studyType":53,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100456469","manual-implantation-of-full-thickness-skin-microcolumns-100456469","NCT05223998","Manual Implantation of Full-Thickness Skin Microcolumns","Manual Implantation of Full-Thickness Skin Microcolumns for 'Donor-Free' Skin Renewal","Inclusion Criteria:\n\n* 8-85 years of age\n* 10-125 cm2 open wound on the scalp, neck, torso or extremities necessitating tissue coverage\n* Sufficiently healthy skin to serve as a donor site\n\nExclusion Criteria:\n\n* Wound area involving the face\\*\n* Wound area involving joints\\*\n* Pregnancy\n* Prisoner\n* Active wound infection at potential treatment sites\n* Exposed muscle, joint, tendon, or bone within the wound bed",{"count":97,"type":20},10,[55],"The objective of this study is to validate the proof of concept regarding the approach of manual implantation of full-thickness skin microcolumns (FTSMs) as coverage for open wounds without creating an additional donor scar and while also capitalizing on the wound healing benefits offered by full-thickness skin grafts.",[58,59],"2024-10-17",{"date":103,"type":35},"2024-10-18",{"date":105,"type":20},"2024-11-04",{"date":107,"type":20},"2025-09-29",{"name":41,"class":42},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":53,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":43},"100455945","phase-4-pilot-study-kerastat-gel-for-topical-delivery-of-morphine-for-management-of-non-healing-painful-open-wounds-and-ulcers-100455945","NCT05217160","Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers","Inclusion Criteria:\n\n1. Subjects age 18 or older able to provide informed consent.\n2. Ulcer size 1-300 cm2\n\n4\\. Undermining\u002Ftunneling \\\u003C3 cm from wound margin 5. Grossly free of necrotic and\u002For infected tissue 6. Baseline minimum of 2 on VAS pain scale\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded from the study:\n\n1. Known allergy to the standard of care or any of the ingredients in KeraStat® Gel or to morphine\n2. Wound has heavy or high-volume exudate or necrotic tissue\n3. Clinical signs of infection or contamination of the wound\n4. Subjects unable to complete the VAS pain score in pain journal\n5. Pregnant or nursing\n6. Prisoner\n7. Any condition the Investigator determines will compromise subject safety or prevent the subject from completing the study",{"count":75,"type":20},[117],"PHASE4","This study is intended to provide information from subjects who currently have painful, chronically open wounds and assess the pain reduction capacity of KeraStat® Gel with Morphine. In gathering data from subjects who have baseline pain from their chronically open wounds, the investigators can then evaluate the capacity of KeraStat® Gel plus Morphine in reducing the subjects daily pain levels, pain associated with dressing changes, and pain medication consumption.",[58,59],"2022-01-19",{"date":122,"type":35},"2022-02-01",{"date":124,"type":35},"2021-05-11",{"date":126,"type":20},"2022-05-31",{"name":41,"class":42},""]